Clinical trials: Nonsmall Cell Lung Cancer Stage III
NSCLC
Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer
Stratification of postoperative ctDNA status can effectively assess the risk of recurrence in patients. In addition, the multi-node dynamic monitoring of ctDNA is more effective in predicting the recurrence risk of patients.
- Trial name
- MRDinS3LC (NCT06081777)
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Peking University Cancer Hospital & Institute
Carcinoma, Non-Small-Cell Lung
A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC
The goal of this phase II, open-label, single-arm study is to evaluate the efficacy and safety of induction immunotherapy and chemotherapy followed by the multidisciplinary team (MDT)-guided radiotherapy or surgery in…
- Trial name
- NCT05940532
- Testing
- Sugemalimab and Chemotherapy
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Hunan Cancer Hospital
Oncology, NSCLC Stage IV
Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer
A Randomized, Multicenter Study Investigating Efficacy and Safety of anti-PD-1/PD-L1-treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer.
- Conditions
- Oncology, NSCLC Stage IV, NSCLC, Stage III
- Trial name
- LUNGVAC (NCT05344209)
- Testing
- UV1, Sagramostim, Anti-PD-1/PD-L1 treatment
- Where
- Norway
- Volunteers
- 138 people
- Sponsor
- Vestre Viken Hospital Trust
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer
The purpose of this study is to evaluate the addition of cisplatin to first-line chemotherapy with gemcitabine in elderly patients with non small cell lung cancer in terms of overall survival.
- Trial name
- MILES-3 (NCT01405586)
- Testing
- Gemcitabine, Cisplatin
- Where
- 49 sites in Italy
- Volunteers
- 299 people
- Sponsor
- National Cancer Institute, Naples
Lung Cancer Stage III
A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants
Primary Evaluate safety and toxicity of AN0025 in both the consolidative setting (after chemoradiation) and in the concurrent setting (during chemoradiation) Evaluate efficacy by progression-free survival (PFS), objective…
- Trial name
- NCT05358691
- Testing
- AN0025
- Where
- United States
- Sponsor
- Rutgers, The State University of New Jersey
Non Small Cell Lung Cancer
Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer
Single center, single arm, Phase II study designed to evaluate the feasibility of hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with 4D PET/CT-based radiation treatment planning and concurrent carboplatin and…
- Trial name
- NCT03699033
- Testing
- 2.5 Gy/fraction, Carboplatin, Paclitaxel
- Where
- United States
- Sponsor
- Stephanie Smiddy
Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)
To investigate the efficacy and safety of BIBW 2992 compared to standard first-line chemotherapy in patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation
- Trial name
- NCT01121393
- Testing
- Gemcitabine+Cisplatin, BIBW 2992
- Where
- 36 sites in China, South Korea and 1 more
- Volunteers
- 364 people
- Sponsor
- Boehringer Ingelheim
Adenocarcinoma of the Lung, Recurrent Non-small Cell Lung Cancer
Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer
This pilot clinical trial studies low-dose acetylsalicylic acid in treating patients with stage I-III non-small cell lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Recurrent Non-small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer
- Trial name
- NCT01707823
- Testing
- acetylsalicylic acid, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Non Small Cell Lung Cancer
Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
The purpose of this multi-center Phase II trial is to examine the impact of pemetrexed/carboplatin in the preoperative treatment of patients with select stage IB, II,and III non-squamous NSCLC.
- Trial name
- NCT00906282
- Testing
- Pemetrexed, Carboplatin
- Where
- 12 sites in United States
- Volunteers
- 46 people
- Sponsor
- SCRI Development Innovations, LLC
Non Small Cell Lung Cancer Stage III
An International Study on the Use of PET/CT in Radiotherapy Planning in Low and Middle Income Countries
A part retrospective, part prospective cohort study to assess the difference in 2-year overall survival in patients with stage III NSCLC receiving chemoradiotherapy with curative intent in low and middle income countries before…
- Trial name
- PERTAIN (NCT02247713)
- Volunteers
- 520 people
- Sponsor
- The Netherlands Cancer Institute
Lung Cancer
Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00117962
- Testing
- cetuximab, carboplatin, pemetrexed disodium
- Where
- 71 sites in United States
- Volunteers
- 109 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-Squamous Non-Small Cell Lung Cancer
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of onartuzumab in combination with erlotinib in patients with previously untreated, unresectable stage IIIB or IV…
- Trial name
- NCT01887886
- Testing
- erlotinib, onartuzumab
- Where
- 35 sites in United States, France and 6 more
- Volunteers
- 10 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer Stage III
Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab
Lung cancer presents a significant treatment challenge, particularly in the heterogeneous stage III NSCLC patient population. While chemotherapy combined with high-dose radiotherapy (60 Gy in 30 fractions of 2 Gy once daily) is…
- Trial name
- CROWD (NCT06908070)
- Testing
- Consolidation durvalumab
- Where
- Netherlands
- Volunteers
- 38 people
- Sponsor
- Idris Bahce
Carcinoma, Non-Small-Cell Lung
A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer
This is a Phase 3, randomized, double-blind, placebo-controlled multicenter global study designed to compare the efficacy and safety of tislelizumab in combination with concurrent chemoradiotherapy (cCRT) followed by tislelizumab…
- Trial name
- RATIONALE001 (NCT03745222)
- Testing
- Tislelizumab, Concurrent chemoradiotherapy (cCRT)
- Where
- 164 sites in United States, Belgium and 21 more
- Volunteers
- 1 people
- Sponsor
- Celgene
Lung Cancer, Carcinoma, Non-Small Cell Lung
Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab
This study is designed to determine if combining consolidative radiation therapy (RT) using a hypofractionated regimen (hfRT) (2 fractions) for boosting the residual primary lung cancer with adjuvant anti-PD-L1 therapy…
- Trial name
- NCT04748419
- Testing
- consolidative hypofractionated radiation therapy (hfRT), Durvalumab 50 MG/ML
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Nebraska
Breast Cancer, Esophageal Cancer
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells of by stopping them from dividing.
- Conditions
- Breast Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer
- Trial name
- NCT01172028
- Testing
- Taxotere (Docetaxel), Alimta (Pemetrexed)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Arizona
Non Small Cell Lung Cancer
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
ADOPT-lung is an international, multicentre, open-label randomised phase III trial. Protocol treatment consists of 3-4 cycles of neoadjuvant durvalumab in combination with platinum-based doublet chemotherapy, followed by surgery.
- Trial name
- ADOPT-lung (NCT06284317)
- Testing
- Adjuvant durvalumab
- Where
- 42 sites in Australia, Austria and 8 more
- Volunteers
- 290 people
- Sponsor
- ETOP IBCSG Partners Foundation
Non-Small Cell Lung Cancer
First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia
The purpose of this study is to compare gefitinib with carboplatin / paclitaxel doublet chemotherapy given as first line treatment in terms of progression free survival in selected NSCLC patients with the objective of…
- Trial name
- IPASS (NCT00322452)
- Testing
- Gefitinib, Carboplatin, Paclitaxel
- Where
- 56 sites in China, Hong Kong and 7 more
- Volunteers
- 1,329 people
- Sponsor
- AstraZeneca
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
The purpose of this study is to assess the efficacy of selumetinib in combination with docetaxel (75mg/m2) vs placebo in combination with docetaxel (75mg/m2) in patients with locally advance or metastatic NSCLCs that harbor…
- Trial name
- SELECT-1 (NCT01933932)
- Testing
- Selumetinib, Docetaxel, Pegylated G-CSF
- Where
- 197 sites in United States, Argentina and 24 more
- Volunteers
- 510 people
- Sponsor
- AstraZeneca
Stage III Non-small-cell Lung Cancer
Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC
Elderly (age 70 years or older) or >18 years old AND poor risk (ECOG 2) newly diagnosed stage IIIA-C (AJCC 8th edition) inoperable non-small cell lung cancer (NSCLC) patients are eligible to participate in this phase II open…
- Trial name
- ESR1814205 (NCT04441138)
- Testing
- Durvalumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Rush University Medical Center